Navigation Links
Sanofi-aventis Announces Second Quarter 2009 Results
Date:7/29/2009

net sales held steady at euro 438 million.

First-quarter net sales of Copaxone((R)) were up 16.5% at euro 118 million. The end of commercialization of this product by sanofi-aventis in North America - effective April 1, 2008 - led to a 44% decline in net sales over the first half.

OTC

Second-quarter net sales for the OTC business were 23.1% higher at euro 311 million (4.4% higher on a constant structure basis and at constant exchange rates), reflecting good organic growth and the consolidation of Symbion and of Zentiva's OTC activities. The six flagship brands (Doliprane((R)), Essentiale((R)), Maalox((R)), No-Spa((R)), Enterogermina((R)), Lactacyd((R))) achieved robust growth of 12.9% and represented 38% of OTC net sales. Russia and Mexico reported good performances for the quarter. First-half net sales for the OTC business were up 16.2% at euro 640 million (3.0% growth on a constant structure basis and at constant exchange rates).

Generics

The Generics business was boosted in the second quarter, with the consolidation of Zentiva and Kendrick (both from April 1) and Medley (from May 1) leading to net sales more than tripling relative to the comparable period of 2008 (to euro 284 million). On a constant structure basis and at constant exchange rates, growth was 6.4%. Rapid progress is being made on combining the Group's generics activities with those of Zentiva, while preserving the autonomy and flexibility to which Zentiva owes its success. First-half net sales for the Generics business were up 129.7% at euro 377 million (8.8% growth on a constant structure basis and at constant exchange rates).

Human Vaccines

Second-quarter consolidated net sales for the Human Vaccines business were down 0.8% at euro 712 million. The figure for the quarter includes $32.5 m
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
5. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
6. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
8. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
9. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... SAN BRUNO, Calif. , Nov. 18, 2014 ... is a platinum sponsor of the 10th Annual World Stem ... and regenerative medicine stakeholders. The 2014 World Stem Cell Summit ... San Antonio, Texas . ... the discovery and development of lifesaving cures and therapies, convening ...
(Date:11/18/2014)... Athena Signature Series: Turning Cancer ‘Off’ – ... a professor in the Regulatory Biology Laboratory at the Salk ... points to an “off switch” for drug resistance in cancer. ... local research is making a global impact in the fight ... join host Cheryl K. Goodman, CEO of Social Global Mobile ...
(Date:11/18/2014)... Texas (PRWEB) November 18, 2014 ... Polytetrahydrofuran (PTMEG) Industry is professional and in-depth ... gives Polytetrahydrofuran basic information, including its definition, ... also industry outline. This exploration covers the ... and worldwide industry examination covering macroeconomic environment ...
(Date:11/18/2014)... 2014  Great Basin Scientific, Inc. (NASDAQ: GBSN ... will host a conference call and webcast to provide an ... Nov. 20, at 4:30 pm EST time. "We ... Company,s recent IPO and would like to provide our investors ... Ryan Ashton , President and Chief Executive Officer of Great ...
Breaking Biology Technology:Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3Great Basin Scientific Announces Conference Call to Provide Update on Corporate Progress 2
... Ambulance Established in Monterrey, MONTERREY, Mexico, and ... Sangui BioTech GmbH,executives jointly opened another wound management ... occasion of a three day working visit. Sangui,BioTech ... Renate Pentzien discussed the next steps of the ...
... approach to a more effective sunscreen , Chronic ... developing skin cancer because UV light from the sun can ... grow in an uncontrolled manner. Hope for a new sunscreen ... been provided by a new study in a mouse model ...
... WALTHAM, Mass., Dec. 3 Thermo Fisher,Scientific Inc. (NYSE: ... today,announced that the China Doping Control Center (CDCC) has ... instrumentation and software for,the testing of athletes at the ... by the Chinese government and the International Olympic,Committee (IOC) ...
Cached Biology Technology:Sangui Partnership Enters a New Phase: 2Sangui Partnership Enters a New Phase: 3Sangui Partnership Enters a New Phase: 4JCI table of contents: Dec. 3, 2007 2JCI table of contents: Dec. 3, 2007 3JCI table of contents: Dec. 3, 2007 4JCI table of contents: Dec. 3, 2007 5JCI table of contents: Dec. 3, 2007 6JCI table of contents: Dec. 3, 2007 7JCI table of contents: Dec. 3, 2007 8JCI table of contents: Dec. 3, 2007 9JCI table of contents: Dec. 3, 2007 10JCI table of contents: Dec. 3, 2007 11JCI table of contents: Dec. 3, 2007 12JCI table of contents: Dec. 3, 2007 13Thermo Fisher Scientific Selected by China Doping Control Center to Supply Testing Instrumentation for the 2008 Olympic Games in Beijing 2Thermo Fisher Scientific Selected by China Doping Control Center to Supply Testing Instrumentation for the 2008 Olympic Games in Beijing 3Thermo Fisher Scientific Selected by China Doping Control Center to Supply Testing Instrumentation for the 2008 Olympic Games in Beijing 4
(Date:11/6/2014)... TALLAHASSEE, Fla. -- A groundbreaking paper from a team ... better understanding of how plants could adapt to and ... The research, published in the latest issue of the ... how chromatin (the complex of DNA and proteins) is ... material, so that some genes are turned on and ...
(Date:11/6/2014)... Baltimore, MD, November 6, 2014 - Insilico Medicine, ... in aging and age related diseases announced a ... medicine of cancer, Champions Oncology, Inc (OTC: CSBR). ... genomics for personalized medicine, but Champions Oncology,s TumorGraft ... can validate the chemotherapy regimen experimentally generating vast ...
(Date:11/5/2014)... Rio de Janeiro, Brazil -Individuals show great diversity in ... importantly, males and females greatly differ in their perceptual ... kinds of smell tests. , Sex differences ... social behaviors and may be connected to one,s perception ... and emotions. Thus, women,s olfactory superiority has been suggested ...
Breaking Biology News(10 mins):Maize analysis yields whole new world of genetic science 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2The female nose always knows: Do women have more olfactory neurons? 2
... EUREKA Chairmanship 2009/2010! The conference, hosted and conceptually designed ... be held on July 6-7, 2009, at Maritim Hotel ... heart of the city, only a few steps away ... the current and future opportunities and challenges for Europe,s ...
... used by millions worldwide to effectively lower blood cholesterol ... Sclerosis (MS) patients treated with high daily dosages. ... Institute (MNI), McGill University, demonstrates that statin therapy in ... nervous system. The findings, published in The American ...
... to model in mice because their symptoms are complex ... when transferred to a mouse. The lack of animal ... By strategically altering a protein-making molecule, a mouse was ... feeling and cause paralysis of the arms and legs ...
Cached Biology News:One size does not fit all 2A new mouse model provides insight into genetic neurological disorders 2
Alexa Fluor 647 anti-mouse Qa-2...
... 100 IS System is ideal for developing ... reagents. This system contains the new, improved, ... Luminex. The user can design specific templates ... system has fully integrated graphing and data ...
Mouse monoclonal [0.T.81] to Lac1 ( Abpromise for all tested applications). Antigen: Recombinant TrpE fusion protein containing full length E. coli Lac1....
... Sweep- based acquision and analysis ... response type applications. Contains powerful ... flexible analysis functions including automated ... plotting. Also includes many electrophysiology ...
Biology Products: